Strata Critical Medical, Inc. (SRTA) Stock Price & Analysis
Strata Critical Medical, Inc. (SRTA) closed at USD 4.71 on Thursday, October 22, 2026, down 0.42% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 4.71; the Oct 22, 2026 session ranged USD 4.66–4.78 on volume of 688,247 shares. Market capitalization is —, with a 52-week range of USD 3.95–6.5 (NCM). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SRTA.md
Key facts (SRTA)
- Last four reported quarters (through Jun 30, 2026): revenue $256M, net income $40.2M (15.7% margin), free cash flow -$48.4M (SEC filings).
- 2 of 80 tracked superinvestors hold SRTA (13F, Q2 2026): 0 new, 1 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $832K; 5 not under a Rule 10b5-1 plan ($450K); 2 by opportunistic insiders (2 outside 10b5-1 plans), 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 9.56 (range 8–12.75).
- Total return with dividends: 1Y -6.4% vs S&P 500 +14.9%; 5Y -51.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD -0.01, revenue estimate $72.7M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SRTA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $50.5M | $146M | $225M | $147M | $197M | $256M |
| Gross profit | $10.5M | $22.3M | $42.1M | $29.6M | $41.1M | — |
| Operating income | -$24.1M | -$53.5M | -$68.1M | -$22.5M | -$22.4M | -$20.4M |
| Net income | -$40.1M | -$27.3M | -$56.1M | -$27.3M | $41.3M | $40.2M |
| EPS (diluted) | -$0.93 | -$0.38 | -$0.76 | -$0.35 | $0.50 | — |
| Free cash flow | -$15.9M | -$37.9M | -$34.5M | -$33.4M | -$58.5M | -$48.4M |
| Gross margin | 20.8% | 15.2% | 18.7% | 20.2% | 20.9% | — |
| Operating margin | -47.7% | -36.6% | -30.3% | -15.3% | -11.3% | -8.0% |
| Net margin | -79.3% | -18.7% | -24.9% | -18.6% | 21.0% | 15.7% |
| Revenue growth | — | — | +54.1% | -34.8% | +34.3% | — |
| Cash + short-term investments | $304M | $192M | $166M | $127M | $61.2M | — |
| Total debt | — | $0K | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SRTA)
P/E at fiscal year-ends: Dec 2025 9.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (SRTA)
2 of 80 tracked investors hold SRTA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Daniel Loeb | Third Point | 0.57% | $26.4M | Unchanged |
| First Eagle Investment | First Eagle Investment Management | 0.02% | $12.2M | Added +2.1% |
Insider sales (SEC Form 4, open-market, last ~7 months) (SRTA)
2 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Love Reginald | Director | 5,091 | $29K | 3.4% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-08 | Heyburn William A. | Co-CEO and CFO | 31,671 | $186K | 2% | No | Routine (traded in Dec each year 2023–2025; this trade is outside those months) |
| 2026-06-08 | Cohen Amir | Chief Accounting Officer | 4,655 | $27K | 3.1% | No | Too little history (no open-market trades in 2025) |
| 2026-06-08 | Tomkiel Melissa M. | Co-CEO and General Counsel | 29,730 | $175K | 1.5% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-08 | Wunsch Scott M | CEO, Logistics | 5,550 | $33K | 0.5% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-05-21…2026-05-22 | Cohen Amir | Chief Accounting Officer | 50,875 | $299K | 25.2% | Yes (adopted December 10, 2025) | Too little history (no open-market trades in 2025) |
| 2026-05-11 | Cohen Amir | Chief Accounting Officer | 14,306 | $83K | 6.6% | Yes (adopted December 10, 2025) | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (SRTA)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 9.56 (low 8, high 12.75).
Total return (dividends reinvested) (SRTA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -6.4% | -51.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -6.4% | -13.3% |
| Volatility (annualized) | 53.7% | 66.1% |
| Max drawdown | -33.9% (May 2026→Oct 2026) | -79.1% (Nov 2021→Oct 2023) |
SRTA revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Logistics | $48.2M | 66.5% | +6.9% |
| Clinical | $24.3M | 33.5% | — |
| Total revenue | $72.5M | 100% | — |
SRTA revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Transplant Clinical | $12.5M | 17.3% | — |
| Other Clinical | $11.7M | 16.2% | — |
| Total revenue | $72.5M | 100% | — |
SRTA revenue by region (quarter ended Jun 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $62.4M | 88.2% | +7.7% |
| Non Us | $8.4M | 11.8% | -16.0% |
| Total revenue | $70.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
SRTA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Trinity Air Medical | “We also utilize proprietary technology to manage staffing, training and chain of custody, as well as help customers streamline organ evaluation (through our Trinity Organ Placement Services - TOPS), procurement and logistics.” |
| Partner | Keystone Perfusion Services | “•our ability to realize the anticipated benefits of strategic transactions, including the recently completed divestiture of the Passenger business, the acquisition and integration of Keystone (as defined below), and any future acquisitions or partnerships;” |
Quoted from the company's 10-K filed Mar 3, 2026.
SRTA customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 10% of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name it.
SRTA company outlook (results filed Aug 4, 2026)
- “We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results. 5 Use of Non-GAAP Financial Information Strata believes that the non-GAAP measures discussed below, viewed in addition to and not”
Quoted word-for-word from the SEC 8-K results press release.
SRTA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.01 | $-0.02 | -62.5% | $72.7M | 4 |
| Next quarter (ends Dec 2026) | $0.01 | $-0.02 | -150.0% | $78.3M | 4 |
| Current fiscal year (ends Dec 2026) | $-0.09 | $-0.07 | +32.1% | $290.8M | 4 |
| Next fiscal year (ends Dec 2027) | $0.00 | $-0.01 | -125.0% | $326.1M | 3 |
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 4.71 |
|---|---|
| Change | ▼ 0.42% (down) |
| Previous Close | USD 4.71 |
| Open | USD 4.71 |
| Day Range | USD 4.66 – 4.78 |
| 52-Week Range | USD 3.95 – 6.5 |
| Volume | 688,247 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (SRTA)
Nexqual's technical model rates SRTA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.97 (neutral) |
| vs SMA50 | Below (USD 5.25) |
| MACD | -0.18 (negative) |
Analyst Ratings (SRTA)
Wall Street analysts rate SRTA "Buy" based on 4 analysts, with a mean price target of USD 9.56 (range USD 8–12.75), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 9.56 |
| High Target | USD 12.75 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SRTA)
| Next Earnings Date | 2026-11-09 |
|---|---|
| Revenue Estimate | $72.67M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.12 vs est -0.02 ▼ miss |
| 2026-03-31 | USD 0.04 vs est -0.04 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.01 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.02 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (SRTA)
| Total Revenue | $255.98M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +60.70% |
| Gross Margin | +21.25% |
| Operating Margin | -6.32% |
| Profit Margin | +15.71% |
| ROE | -9.22% |
| Debt / Equity | 0.02 |
| Current Ratio | 2.64 |
| Total Cash | $22.75M |
| Total Debt | $4.25M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$48.45M (-18.9% of revenue) |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (SRTA)
Nexqual rates Strata Critical Medical, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Critical — Revenue -21% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 21%, operating -6% (last 12 months) |
| Balance Sheet | Strong — $23M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$48M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -9%, ROA -1.9% |
Ownership (SRTA)
| Insider Ownership | +14.32% |
|---|---|
| Institutional Ownership | +71.81% |
| Shares Outstanding | 88.47M |
| Float | 57.98M |
| Short % of Float | +6.21% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
From Strata Critical Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- We also utilize proprietary technology to manage staffing, training and chain of custody, as well as help customers streamline organ evaluation (through our Trinity Organ Placement Services - TOPS), procurement and logistics.
- Our technology enhances the efficiency and cost-effectiveness of our service offerings, further strengthening our position in the organ transportation industry.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business is subject to a wide variety of extensive and evolving laws and regulations, which may result in increases in our costs, disruptions to our operations, limits on our operating flexibility, and competitive disadvantages.
- We could be subject to litigation or regulatory investigations, which may be expensive and could divert management attention.
- Failure to comply with laws and regulations relating to privacy, data protection, cybersecurity, healthcare information, and consumer protection, or the expansion of current laws and regulations or the enactment of new laws or regulations in these areas, could adversely affect our business and our financial condition.
- Failure to comply with applicable healthcare, privacy, security and data protection laws and regulations could result in a material breach of contract with one or more of our Medical Customers, subject us to enforcement actions and adversely affect our business and our financial condition.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INNV | InnovAge Holding Corp. | USD 9.52 | ▲ 4.16% |
| USPH | U.S. Physical Therapy, Inc. | USD 88.73 | ▲ 2.84% |
| NUTX | Nutex Health Inc. | USD 206.09 | ▲ 4.29% |
| PNTG | The Pennant Group, Inc. | USD 42.23 | ▲ 2.9% |
| AGL | agilon health, inc. | USD 90.29 | ▼ 0.77% |
| CMPS | COMPASS Pathways Plc - American | USD 11.63 | ▼ 1.77% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt